Post‐Coronavirus Disease (COVID)‐19 Irritable Bowel Syndrome: What We've Learned So Far

Jan 24, 2026Neurogastroenterology and motility

Irritable Bowel Syndrome After COVID-19: What We Know So Far

AI simplified

Gut-Brain Axis on OpenScience ↗PubMed ↗DOI ↗

Abstract

Approximately 7.2% of individuals develop irritable bowel syndrome after SARS-CoV-2 infection.

Individuals infected with SARS-CoV-2 have 2.6-fold higher odds of developing IBS compared to non-infected controls.
A U.S. survey of over 160,000 adults indicated a surge in IBS prevalence during the pandemic, primarily IBS-M, alongside a modest rise in chronic idiopathic constipation.
Mechanisms contributing to post-COVID-19 IBS are multifactorial, involving gut-related biological changes, persistent inflammation, and psychosocial stress.
Emerging evidence suggests that symptoms such as dyspnea and depression may further influence the development of IBS following COVID-19.
There is a recommendation for a positive diagnosis framework and multidisciplinary care tailored to individual patient phenotypes.

AI simplified

BACKGROUND: The COVID-19 pandemic has unveiled a hidden epidemic of disorders of gut-brain interaction (DGBIs), notably post-infection irritable bowel syndrome (PI-IBS), driven by SARS-CoV-2 GI tropism and pandemic stressors.

PURPOSE: This review synthesizes and critically appraises current evidence on the prevalence, clinical spectrum, and predictors of post-COVID-19 IBS, integrating mechanistic insights. Topics discussed in this review will advance understanding of pathophysiological mechanisms, identify therapeutic targets, inform phenotype-tailored management and clinical care, and outline research priorities for post-COVID-19 IBS.

METHODS: A narrative review was performed by the authors.

KEY RESULTS: Recent evidence indicates that approximately 7.2% of individuals develop IBS after SARS-CoV-2 infection, with 2.6-fold higher odds vs. non-infected controls. At the population level, a nationally representative U.S. survey (> 160,000 adults) showed a pandemic-era surge in IBS prevalence (predominantly IBS-M) and a modest increase in chronic idiopathic constipation (CIC), while other Rome IV DGBIs remained stable. Mechanisms are multifactorial, involving ACE2-linked epithelial/neuromuscular effects, persistent low-grade inflammation, microbiota dysbiosis with reduced short-chain fatty acids, altered serotonin signaling, barrier dysfunction, and psychosocial stress acting along the gut-brain axis. Emerging data indicate dyspnea and depression further mediate the COVID-19-to-IBS pathway, underscoring biopsychosocial endotypes.

CONCLUSIONS AND INFERENCES: This review indicates that following infection with SARS-CoV-2, DGBI, particularly IBS, occurs in 7.2% patients on follow-up. Clinically, a positive diagnosis framework and phenotype-tailored, multidisciplinary care are recommended. Future studies on post-infection IBS including post-COVID-19 IBS should be undertaken using upcoming Rome V criteria, controlling for confounding factors, and defining mechanistic endotypes to unlock precision therapies.

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text (XML) ↗View full text ↗

Post‐Coronavirus Disease (COVID)‐19 Irritable Bowel Syndrome: What We've Learned So Far

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the gut-brain axis brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the gut-brain axis brief